1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 11,700 | 14,800 | 12.09. |
Chart-Typ:
Zeitraum:
| Dividendenbekanntmachungen (03.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIRAL GROUP PLC GB00B02J6398 0,705 GBP 0,8204 EUR AEGON LTD ADR US0076CA1045 0,2455 USD 0,2118 EUR AMCOR PLC CDIS AU000000AMC4 0... ► Artikel lesen |
| Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen |
| Clinuvel Pharmaceuticals Limited: CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study | EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its "totality of evidence" approachcentral photographic review and validated disease... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen |
| BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer | PARIS (dpa-AFX) - BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect.In... ► Artikel lesen |
| BioCryst Pharmaceuticals, Inc.: BioCryst Appoints David W. Jenkins as Chief Scientific Officer | RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) ("BioCryst" or the "Company") today announced the appointment of David W. Jenkins, MA... ► Artikel lesen |
| Cardiol Therapeutics Inc.: Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities Commission | TORONTO, Sept. 10, 2026 /PRNewswire/ -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen |
| Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen |
| Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADLAI NORTYE GROUP LTD ADR finden Sie auf Wallstreet Online.